このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

MediPharm Labs マネジメント

マネジメント基準チェック /34

MediPharm Labs'の CEO はDavid Pidduckで、 Apr2022年に任命され、の在任期間は 2.17年です。の年間総報酬はCA$ 1.31Mで、 36%給与と64%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の3.3%を直接所有しており、その価値はCA$ 1.00M 。経営陣と取締役会の平均在任期間はそれぞれ4.7年と5年です。

主要情報

David Pidduck

最高経営責任者

CA$1.3m

報酬総額

CEO給与比率	36.0%
CEO在任期間	2.2yrs
CEOの所有権	3.3%
経営陣の平均在職期間	4.7yrs
取締役会の平均在任期間	5yrs

経営陣の近況

Recent updates

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11

CEO報酬分析

MediPharm Labs の収益と比較して、David Pidduck の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-CA$14m
Dec 31 2023	CA$1m	CA$470k	-CA$13m
Sep 30 2023	n/a	n/a	-CA$16m
Jun 30 2023	n/a	n/a	-CA$19m
Mar 31 2023	n/a	n/a	-CA$26m
Dec 31 2022	CA$3m	CA$315k	-CA$30m

報酬と市場: Davidの総報酬 ($USD 951.36K ) は、 Canadian市場 ($USD 177.17K ) の同規模の企業の平均を上回っています。

報酬と収益: Davidの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

David Pidduck

2.2yrs

在職期間

CA$1,305,051

報酬

Mr. David A. Pidduck is Chief Executive Officer and Director at MediPharm Labs Corp. since April 20, 2022. Mr. Pidduck has been the Chief Executive Officer and President of Purdue Pharma Inc. since Septemb...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Pidduck	CEO & Director	2.2yrs	CA$1.31m	3.3% CA$ 934.3k
Keith Strachan	Co-Founder & President	5.3yrs	CA$819.48k	0.51% CA$ 143.5k
Greg Hunter	Chief Financial Officer	3.3yrs	CA$957.75k	0.21% CA$ 59.7k
Patrick McCutcheon	Founder	9.4yrs	CA$858.16k	データなし
Brett Moon	Vice President of Sales	4.1yrs	データなし	データなし
Kirk Binns	Executive Vice President of Global Accounts	5.3yrs	データなし	データなし

4.7yrs

平均在職期間

経験豊富な経営陣: LABSの経営陣は経験豊富であると考えられます ( 4.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
David Pidduck	CEO & Director	2.2yrs	CA$1.31m	3.3% CA$ 934.3k
Shelley Martin	Independent Director	4yrs	CA$64.49k	データなし
Michael Bumby	Independent Director	1.2yrs	CA$34.45k	0.029% CA$ 8.1k
Christopher Taves	Independent Chairman of the Board	3.9yrs	CA$87.14k	0.25% CA$ 70.0k
Miriam McDonald	Member of the Science Advisory Board	5.2yrs	CA$32.40k	データなし
Leslie Brown	Member of the Science Advisory Board	5.2yrs	データなし	データなし
Matt Archibald	Member of the Science Advisory Board	5.2yrs	データなし	データなし
Markus Roggen	Member of the Science Advisory Board	5.2yrs	データなし	データなし
Arshad Hack	Member of the Science Advisory Board	5.2yrs	データなし	データなし
Jerry King	Member of the Science Advisory Board	5.2yrs	データなし	データなし
Carolina Landolt-Marticorena	Member of the Science Advisory Board	4.8yrs	データなし	データなし
Christopher Halyk	Independent Director	3.8yrs	CA$56.05k	0.021% CA$ 6.0k

5.0yrs

平均在職期間

経験豊富なボード: LABSの取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

MediPharm Labs マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

CEO & Director exercised options to buy CA$130k worth of stock.

CEO & Director exercised options to buy CA$89k worth of stock.

CEO & Director exercised options to buy CA$93k worth of stock.

High number of new and inexperienced directors

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

Recent updates

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

MediPharm Labs (TSE:LABS) Is Using Debt Safely

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

Consensus estimates of losses per share improve by 25%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

New minor risk - Share price stability

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 11%

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

CEO & Director exercised options to buy CA$130k worth of stock.

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

CEO & Director exercised options to buy CA$89k worth of stock.

CEO & Director exercised options to buy CA$93k worth of stock.

Consensus EPS estimates upgraded to CA$0.045 loss, revenue downgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Consensus revenue estimates increase by 47%, EPS downgraded

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Consensus revenue estimates fall by 20%

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to CA$0.25

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Consensus revenue estimates fall by 13%

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold CA$87k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to CA$0.65

MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Founder & Chairman of the Board recently sold CA$483k worth of stock

マネジメント基準チェック /34